Target intelligence / Profile preview

Tubulin alpha chain and Tubulin beta chain (heterodimer, microtubule subunits) (α-tubulin and β-tubulin)

Target
α-tubulin and β-tubulin
Molecular classification
Structural protein (cytoskeleton), Enzyme (GTPase activity), Microtubule subunit, Tubulin superfamily
01

Overview

Tubulin alpha and beta chains are highly conserved globular proteins that form obligate heterodimers, which polymerize to construct microtubules—a key component of the eukaryotic cytoskeleton involved in cell shape, intracellular transport, and mitosis[1][5][6][7][9]. Each monomer binds GTP; the α-tubulin nucleotide is nonexchangeable, while β-tubulin’s nucleotide can hydrolyze and exchange GTP, driving microtubule assembly dynamics[1][6][8]. Tubulin exists in multiple isotypes encoded by distinct genes and is subject to various post-translational modifications, contributing to cellular functions, neuronal development, and disease states[7][9]. Aberrations in tubulin structure, expression, or modification are implicated in cancer, neurodevelopmental disorders, and confer resistance to common chemotherapeutics that directly target microtubules[7][9]. Microtubule-targeting agents are a mainstay in chemotherapy but are limited by side effects and acquired resistance in tumors[7].

Other names
Tubulin alpha-1A chain (TUBA1A)Tubulin beta chainAlpha-tubulinBeta-tubulinTubulin heterodimerMicrotubule protein
02

Mechanism of action

Inhibition of microtubule polymerization (e.g., vincristine, colchicine); Stabilization of microtubules (e.g., paclitaxel, docetaxel); Disruption of mitotic spindle and cell division; Antimicrotubule agent (prevents dynamic instability required for mitosis)

03

Biological functions

Structural support (cytoskeleton)Cell division (mitosis, meiosis)Intracellular transportCell motilityCell shape maintenanceNeuronal migrationRegulation of cell signaling
04

Disease associations

CancerNeurodegenerative diseases (e.g., Alzheimer’s disease, tubulinopathies)Developmental brain disordersInflammatory diseasesDrug resistance in oncology
05

Safety considerations

Neurotoxicity (peripheral neuropathy from microtubule-targeting drugs)MyelosuppressionDrug resistanceOff-target toxicity from effects on normal dividing cellsDevelopmental toxicity
06

Interacting drugs

Paclitaxel (Taxol)

9 more in the full profile.

07

Biomarkers

Tubulin isotype expression (e.g., beta-III tubulin in cancer for drug resistance indication)Post-translational modifications (acetylation, detyrosination, phosphorylation in specific tissue/disease contexts)

Beyond the preview

Go deeper on Tubulin alpha chain and Tubulin beta chain (heterodimer, microtubule subunits) (α-tubulin and β-tubulin).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tubulin alpha chain and Tubulin beta chain (heterodimer, microtubule subunits) (α-tubulin and β-tubulin).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call